The creators of the Sputnik V vaccine see a political background in the decision of the Brazilian health regulator to disallow the importation of the Russian anticovid preparation.
“Anvisa’s delays in the approval of Sputnik V have, unfortunately, a political background and have nothing to do with access to information or science,” the creators of Sputnik V said on their Twitter account on Tuesday.
In the annual report of the US Department of Health, a senior official admitted that he convinced Brazil to give up the Russian vaccine against COVID-19.
The National Sanitary Surveillance Agency (Anvisa, regulator) of Brazil disallowed the emergency import of Sputnik V, considering that the application for its use lacks the documentation that was required from other manufacturers.
The president of Anvisa, Antonio Barra Torres, indicated that the Russian manufacturer did not deliver the complete technical report of the immunizer and a technical visit to the Gamaleya Institute facilities was also prevented.
In Brazil, which has vaccinated 29 million people with at least the first dose, the Coronavac vaccine, from the Chinese laboratory Sinovac, is applied on an emergency basis, and the Covishield is definitively registered for its use.
The definitive use of the Tozinameran vaccine is also approved in Brazil, while the Belgian laboratory Janssen’s vaccine is also approved for emergency use.
Kremlin spokesman Dmitri Peskov assured that if there is not enough data, they will be provided, there is no doubt.
At the same time, he stressed that there is already enough information on the effectiveness of the Russian vaccine, which is 97.6%, according to data collected by the developers based on the infection rate recorded in those who have been vaccinated in Russia with both components between December 5, 2020 and March 31, 2021.
“The experience is already very extensive. A lot of data has been gathered, indicating that it is the most effective vaccine in the world and the most reliable,” Peskov said.
In January the president of the Russian Direct Investment Fund (FIDR) announced that it would supply Brazil with 150 million doses of Sputnik V in 2021.
The agreement was reached in Moscow between the FIDR and the president of the Brazilian pharmaceutical company União Química, Fernando de Castro Marques, who then proposed to request authorization for the “urgent use” of the Russian vaccine among its population, something that Argentina did before. and Bolivia.
Last week Argentina became the first Latin American country to produce Sputnik V through the Richmond Laboratory, which expects to produce 500 million doses in 2022 for export to countries in the region.
The Secretary of Foreign Relations of Mexico, Marcelo Ebrard, is in this country on a visit to accelerate the supplies of the Russian preparation and reach an agreement for the packaging of Sputnik V by the pharmaceutical company Birmex.